Abstract Dramatic improvements have been seen in shortterm kidney allograft survival over recent decades with introduction of more potent immunosuppressant medications and regimens. Unfortunately, improvements in long-term graft survival have lagged behind. The genomics revolution is providing new insights regarding the potential impact of kidney donor genotypes on long-term graft survival. Variation in the donor apolipoprotein L1 (APOL1), caveolin 1 (CAV1), and multi-drug resistance 1 encoding P-glycoprotein genes (ABCB1) are all associated with graft survival after kidney transplantation. Although the precise mechanisms whereby these donor gene variants confer risk for graft loss have yet to be determined, these findings provide novel opportunities for modifying interactive environmental factors and optimizing kidney allocation with the ultimate goal of improving long-term graft survival rates.
Introduction
End-stage kidney disease (ESKD) remains a major public health concern with increasing numbers of prevalent patients on dialysis and recent annual Medicare costs exceeding $29 billion. Kidney transplantation is preferable to dialysis for children and adults with ESKD, leading to improved quality of life and longer patient survival at far lower cost. In 2006, the total Medicare expenditure per person per year was approximately $25,000 for an individual who had received a kidney transplant compared to $75,000 for dialysis [2] . Although 92 % of transplanted kidneys function beyond 1 year, long-term graft loss has remained high despite recent medical advances [3] . As such, new tools are urgently needed to improve long-term graft survival, particularly in pediatric and young-adult patients to ensure normal growth and prolonged physical function.
The risk of chronic kidney disease (CKD) is jointly influenced by genetic and environmental effects. It is intuitive that nephropathy susceptibility gene variants in kidney donors and immune response genes in transplant recipients would have the potential to impact long-term allograft function. Several recent reports have explored the impact of genetic variants in donor kidneys on allograft survival; including risk variants associated with nephropathy susceptibility, altered drug metabolism, and risk of viral entry into cells. Donor kidneys used for transplantation are an ideal model for evaluating the clinical importance of kidney donor genetic predisposition on long-term allograft survival. The combination of reduced nephron mass (transplantation of one kidney) coupled with the environmental stresses of cold ischemia (particularly for deceased donor kidney transplants [DDKT] ) and exposure to nephrotoxic medications (calcineurin inhibitors, CNIs) make kidney transplant genetics clinically relevant. The transplant procedure is similar to partial nephrectomy in rodents with subsequent exposure to nephrotoxins; however, kidney transplantation yields information pertinent to human disease.
This manuscript reviews kidney-donor genetic variants impacting long-term transplant outcomes, including in the apolipoprotein L1 gene (APOL1), which appear to explain the effects of African donor population ancestry on graft survival, the caveolin 1 gene (CAV1) potentially linked to renal fibrosis and/or ascending BK polyoma virus infection, and multi-drug resistance 1 encoding P-glycoprotein gene (ABCB1) impacting drug metabolism. It is highly likely that donor genetic information will be utilized in clinical renal transplantation, providing additional risk stratification beyond traditional risk factors (Table 1 ). In addition, risk variants in APOL1 and potentially other genes may one day inform potential living kidney donors of their risk for nephropathy after donation [4] . It is likely that genetic variation beyond the major histocompatibility locus will soon play an important role in transplant medicine and determination of optimal immunosuppression regimens. In pediatric nephrology, the long-term success of the first kidney transplant is of the utmost importance; subsequent transplants are more likely to have an inferior outcome due to patient sensitization, increased risks of infection and rejection, and the cumulative burden of immunosuppression.
Apolipoprotein L1 gene (APOL1)
The incidence of ESKD in African Americans is 3.4 times higher than in European Americans [1] . APOL1 risk variant allele frequencies fully explain the excess rate of nondiabetic ESKD between African and European ancestry populations, as well as familial clustering of multiple etiologies of ESKD in single African American families [5] [6] [7] . The two nephropathy-associated coding APOL1 risk variants (G1 and G2) are virtually absent in European and Asian populations with frequencies well below 1 % [8, 9] . In contrast, the G1 and G2 risk alleles are very common in African Americans due to positive selection resulting from the survival advantage provided by ApoL1 protein from Trypanosoma brucei rhodesiense-induced African sleeping sickness [5] .
Fifty percent of African Americans possess at least one APOL1 risk allele; approximately 12 % possess two risk alleles and are at substantially increased risk for nondiabetic nephropathy [5] . Possession of two APOL1 risk alleles confers a 29-fold increased risk for HIV-associated nephropathy (HIVAN), a 17-fold increased risk for focal segmental glomerulosclerosis (FSGS), and 7.3-fold increased risk for hypertension-attributed ESKD (now known to be in the spectrum of FSGS and not caused by hypertension) [5, 10, 11] . The frequencies of APOL1 G1 and G2 risk variants appear to be higher among west Africans than African Americans [12] and strikingly lower frequencies of risk variants are found in Ethiopians (east Africa), likely explaining lower rates of HIVAN in Ethiopians despite the presence of HIV [13] . APOL1 risk variants are known to associate with nephropathy in Nigerians, as in African Americans [14] .
In addition to higher rates of ESKD, African Americans also have decreased allograft survival after kidney transplantation [3] . Based on UNOS data from 1994 to 2002, Hwang et al. reported a relative risk of 1.93 for graft loss after 3 months of transplantation in African American children compared to non-African American children [15] . Furthermore, kidneys donated by African Americans have significantly shorter graft survival compared to kidneys donated by European Americans [16] . This effect persists regardless of recipient race [17] .
Recent research indicates that donor APOL1 variants likely explain population ancestry-driven differences in kidney transplant outcomes [18] . Reeves-Daniel et al. investigated the relationship between donor APOL1 risk variants and allograft survival after DDKT. This study included 136 African American donor kidneys from 106 deceased donors, along with their respective recipients (approximately 50 % of recipients were African American). Kidneys from donors with two APOL1 risk alleles had significantly shorter allograft survival relative to donors with 0/1 risk allele. In fact, African American donors without two APOL1 risk variants had similar long-term graft survival as kidneys from European American donors. Differences in allograft survival based on APOL1 genotype distributions were evident after approximately 20 months. Of grafts lost with two APOL1 risk variants, 75 % had biopsy-proven APOL1-associated lesions including FSGS and/or arteriosclerosis, compared to 11.8 % among grafts lost with 0/1 APOL1 risk alleles. Remarkably, the presence of two donor APOL1 risk alleles had a more significant effect on allograft survival than did traditional risk factors such as degree of HLA mismatch, cold ischemia time, and expanded criteria donation [18] . It remains important that these results be replicated at other centers before considering widespread APOL1 genotyping in African ancestry deceased donor kidneys. In contrast to donor genotypes, recipient APOL1 genotypes do not appear to impact allograft outcomes [19] . Lee and colleagues investigated the impact of recipient APOL1 genotypes on allograft survival in 119 African American recipients. Approximately 38 % of respective donors were African American. No difference in allograft survival was evident at 5 years between recipients carrying either two APOL1 risk alleles versus 0 or 1. As genotype data on donors was unavailable, they performed a subgroup analysis including only non-African American donors and African American recipients. Again, no impact of APOL1 recipient genotypes was detected on long-term graft survival [19] .
The mechanism(s) by which APOL1 risk variants cause FSGS, renal microvascular, and interstitial disease in native kidneys and renal allografts are unknown. ApoL1 protein is predominantly synthesized in the liver and circulates in association with plasma high-density lipoprotein (HDL) cholesterol [20] . Madhavan et al. performed immunohistology and demonstrated that ApoL1 protein is present in podocytes, proximal tubules, and the vascular endothelium of normal kidneys [21] . In cases of FSGS and HIVAN, the number of podocytes containing ApoL1 was diminished, and de novo ApoL1 appeared in the media of smooth muscle cells in medium-sized arteries and arterioles. The authors suggested that ApoL1 may be endogenously synthesized by the kidney, contributing to disease pathogenesis, or it may act in concert with uptake of extracellular ApoL1 protein [21] .
The functional role of ApoL1 in the kidney is unknown. Clinically, all individuals carrying two APOL1 risk variants will not develop ESKD. Therefore, either gene-gene and/or gene-environment interactions appear important for disease initiation and nephropathy progression [22, 23] . As it has been shown that donor APOL1 genotypes, not recipient genotypes, impact renal allograft survival, we postulate that high-risk kidney donors may have had occult (subclinical) nephropathy at the time of donation, which when coupled with environmental stressors related to transplantation (prolonged cold ischemia time, CNIs, and/or viral infections with a renal reservoir) could accelerate disease. It is also possible that inflammatory mediators associated with transplantation may induce APOL1 expression in donor kidneys; in the presence of risk variants, this could lead to APOL1-associated nephropathy [18, 19, 21, 24, 25] .
Further insights into the mechanisms of APOL1-associated nephropathy may provide exciting opportunities to alter the significantly decreased long-term graft survival seen with APOL1 donor kidneys containing two risk variants [18] . HIV is an important environmental factor that dramatically increases the likelihood of developing APOL1-associated HIVAN. Since the introduction of highly active anti-retroviral therapy (HAART), the incidence rate of HIVAN has sharply decreased in African Americans. Hence, treating an environmental exposure (for example, viral infections like HIV) has the potential to reduce rates of a genetically mediated kidney disease. As other interactive environmental factors (and interactive gene variants) are identified, there will be the potential to alter the recipient milieu and prevent or ameliorate APOL1-associated kidney disease that results from the donor kidney [23, 26] .
Cohen et al. feel that genotyping African ancestry living kidney donors for the presence of APOL1 risk variants would be informative to them and potentially to recipients of their kidneys [4] . We will strongly advocate for deceased donor genotyping for APOL1 in those with African ancestry upon replication of the findings from our single-center study. APOL1 genotyping may also allow clinicians to counsel potential African American living donors regarding their subsequent post-donation risk for ESKD. It is unknown whether living kidney donation in individuals carrying two APOL1 risk alleles would precipitate or accelerates APOL1-associated nephropathy in the donors; these studies remain critical to perform. However, living kidney donors of African ancestry, compared to European, are known to face higher risk for postdonation ESKD, although overall rates are low and the higher risk in African Americans parallels that seen in the general population [27, 28] . This remains an important area of research. From the recipient perspective, it is likely that donor APOL1 genotyping may allow for better matching of recipient life expectancy and expected graft survival. Similar in concept to ECD kidneys, donor APOL1 genotyping would allow for optimization of kidney allocation, moving the high-risk kidneys with two APOL1 nephropathy variants away from younger recipients with longer estimated post-transplant life expectancy.
Caveolin-1 gene (CAV1)
Caveolin-1 participates in transforming growth factor-β (TGF-β) receptor degradation and may limit the propagation of pro-fibrotic TGF-β signals [29] . Idiopathic pulmonary fibrosis and systemic sclerosis are fibrosing conditions shown to have decreased CAV1 expression in affected organs [30] . CAV1 expression also appears to play a role in other fibrosing kidney disorders. Park et al. showed that the degree of renal fibrosis in a mouse model of transient unilateral ureteral obstruction was inversely related to CAV1 gene expression [31] . CAV1-deficient mice had significantly greater renal fibrosis than did wild-type mice and wild-type animals developed more renal fibrosis than did mice overexpressing CAV1.
After kidney transplantation, interstitial fibrosis is one of the most common causes of allograft failure. Excluding kidneys lost to primary non-function or recipient death with a functioning graft, El-Zoghby et al. reported that approximately 30 % of 1,317 transplanted kidneys in their series failed due to progressive interstitial fibrosis and tubular atrophy (IF/TA) [32] . Among allografts that survived longer than 5 years, approximately 45 % were eventually lost due to IF/TA.
Moore et al. investigated the relationship between kidney transplant outcomes, interstitial fibrosis, and donor and recipient CAV1 gene polymorphisms [33] . Their initial study (discovery sample) was conducted in England and included 785 living and deceased kidney donors with corresponding transplant recipients. All donors were of European ancestry, although 77.8 % of recipients were European, 5.5 % of African ancestry, 16.3 % South Asian, and 0.4 % classified as "other". Univariable and multiple regression analyses adjusting for traditional risk factors for graft loss detected a significantly increased risk for graft loss after 54 months of follow-up among those with donor AA genotypes ("A" denotes the CAV1 risk variant), compared to donor non-AA genotypes. Furthermore, 59 % of graft failures in the donor AA genotype group were due to biopsy-proven interstitial fibrosis as the predominating lesion, relative to 26 % in the donor non-AA genotype group. Other causes of graft loss were similar between donor AA and non-AA genotype groups. The investigators successfully replicated these results in a second study conducted in Ireland. Here, 679 deceased kidney donors and their respective recipients were evaluated. All donors and recipients in the replication sample were of European ancestry and donor AA genotype kidneys again conferred a statistically significant increased risk of graft loss, relative to donor non-AA genotype kidneys. It remains important to consider geographic and ethnic variation in the effects of CAV1 (and other genes) on transplant outcomes; effects of this gene outside of UK and Irish populations remain to be reported and will need to be considered before general application.
Conflicting results were seen with regard to the effects of recipient CAV1 genotype on long-term allograft survival. In the English discovery sample, recipient CAV1 genotypes had no impact on long-term graft outcomes. However, in the Irish replication sample, recipient AA genotypes were associated with significantly higher risk of graft loss. Overall, no conclusions could be drawn with respect to recipient CAV1 genotype on risk of graft loss [33] . The mechanism(s) by which donor CAV1 AA genotypes confer a higher risk of renal graft loss remain to be determined and were not addressed in this report. Caveolin-1 forms the backbone of caveolae, cell-surface invaginations that play critical roles in cell signaling via endocytosis of a variety of toxins, enzymes, and receptors [29, [34] [35] [36] [37] [38] [39] . Caveolin-1 decreases signal transduction of TGF-β by inducing endocytosis of the TGF-β receptor [29] . TGF-β plays a key role in activating pathways, which may ultimately lead to fibrosis in the renal allograft [40] [41] [42] [43] . An attractive, but speculative mechanistic model to explain the findings of Moore et al. [33] includes alterations in donor kidney CAV1 expression level or morphologic variation of caveolin-1 due to gene polymorphisms that limit the ability of the structural protein to attenuate the pro-fibrotic TGF-β signal. This would lead to accelerated interstitial fibrosis and shorter allograft survival.
Another aspect of CAV1 relevant to kidney transplantation is its role in BK polyoma virus-associated nephropathy. BK virus is typically acquired during childhood and remains latent in cells of the kidney and uroepithelium. With immunosuppression, BK virus may enter a replicative phase, producing allograft nephritis with the potential for graft failure. Moriyama et al. reported that replicating BK virus enters nearby uninfected human renal proximal tubule cells through caveolar endocytosis [44] . In the report by Moore et al. evaluating CAV1, the relationship between CAV1 gene polymorphisms and likelihood of developing BK virus nephropathy was not specifically investigated [33] . This remains an important avenue for future research.
Future implications related to donor CAV1 genotyping for clinicians include the potential to modify environmental factors that may act synergistically to promote allograft fibrosis. It is tempting to speculate that deceased donor kidneys with the high-risk CAV1 AA genotype could have improved allograft survival with decreased cold ischemia times or CNI-free immunosuppression; although this remains to be evaluated. In other CAV1-associated fibrosing diseases, increasing the bioavailability of caveolin-1 via genetically engineered vectors may decrease subsequent degrees of fibrosis [30, 31] . This may prove to be a potential therapeutic approach for recipients of CAV1 AA risk genotype donor kidneys. Finally, if relationships exist between CAV1 genotype and susceptibility to BK virus nephropathy, perhaps reductions in the intensity of immune suppression based on this genotypic information could ameliorate disease risk.
Multi-drug resistance 1 encoding P-glycoprotein gene (ABCB1)
Tacrolimus is included in the initial maintenance immunosuppression regimens in 94 % of pediatric kidney transplant recipients [3] . One-year kidney allograft survival rates have significantly improved with the introduction of CNIs, an effect attributed to reductions in acute rejection episodes with these more potent immunosuppressive medications [45] [46] [47] . However, CNIs are nephrotoxic and can contribute to long-term renal graft loss [48] . There is a direct correlation between serum CNI concentrations and anti-rejection effect, as well as nephrotoxicity. This results in a narrow therapeutic window [49] [50] [51] [52] . However, even in the setting of careful CNI drug monitoring there appear to be significant interindividual differences in time to development of CNI-related nephrotoxicity and subsequent progression to ESKD. Genetic polymorphisms relating to CNI pharmacokinetics and pharmacodynamics have received attention as potential mediators of the inter-individual differences in CNI levels and effect, particularly ABCB1 encoding the drug transporter P-glycoprotein.
Woillard et al. first investigated the relationship between donor and recipient ABCB1 C3435T polymorphisms (singlenucleotide polymorphism [SNP] rs1045642) and renal allograft survival in a study investigating 227 French deceased donors and their recipients [53] . They found that donor ABCB1 "TT" variants were associated with a significantly increased risk of graft loss after a mean follow-up of 72 months. Recipient ABCB1 genotypes did not appear to impact allograft survival.
Moore et al. [54] subsequently examined ABCB1 donor genotypes for effects on allograft survival in three distinct cohorts including nearly 4,500 kidney transplants. The initial sample consisted of 811 living and deceased kidney donors with their recipients from England. As in their report evaluating CAV1, 82.1 % of recipients were European, 5.5 % of African ancestry, and 16.3 % South Asian; 100 % of kidney donors were European. Recipients were uniformly maintained on cyclosporine. Recipients receiving a kidney from a donor with the ABCB1 "CC" genotype (C denotes an allele known to alter protein expression) had statistically significant higher rates of graft failure compared to those who received a kidney from a non-CC donor. These results directly conflict with those of Woillard et al. [53] Moore and colleagues then validated their results in two replication samples [54] . The first was from Ireland, and included 675 European deceased donors and their respective recipients (99 % of recipients were European). In this first validation study, 82.5 % of recipients received cyclosporine and 17.5 % tacrolimus. Again, recipients receiving a kidney from a donor with the ABCB1 CC genotype had statistically significant higher rates of graft failure relative to those receiving a non-CC donor genotype kidney.
Moore et al. [54] attempted further replication between donor ABCB1 genotypes and kidney transplant outcomes in the Collaborative Transplant Study (CTS). The CTS cohort included 2,985 North American and European kidney donors with their recipients; 100 % of donors and recipients were of European ancestry. In the CTS, 84.8 % of transplant recipients were treated with cyclosporine and 15.2 % tacrolimus. No significant relationship was identified between donor ABCB1 genotypes and death-censored graft survival in the overall CTS cohort. Heterogeneity of CTS study populations, with patients from different countries and centers using different protocols may have contributed. However, in the subgroup of 452 recipients maintained on tacrolimus maintenance immunosuppression, there was a statistically significant increased risk of graft loss in recipients of a kidney from a donor with the ABCB1 CC genotype, compared to those receiving a kidney from a donor with a non-CC genotype. In the three cohorts assessed by Moore et al., associations were not observed between recipient ABCB1 genotypes and renal graft survival [54] .
The mechanism by which donor ABCB1 genotypes increase the risk for graft loss remains unclear; neither the Woillard et al. [53] or Moore et al. [54] report listed causes of graft loss. P-glycoprotein, the gene product of ABCB1, is a transmembrane protein that actively transports CNIs from the intracellular to the extracellular compartment [55, 56] . Pglycoprotein is expressed in a variety of cells including renal proximal tubule cells [57] . Although both Woillard and colleagues and Moore and colleagues found that donor ABCB1 C3435T polymorphisms were associated with increased risk for renal allograft loss, the associated risk variants differed [53, 54] . The study by Moore et al. [54] found consistent evidence of association between donor ABCB1 CC genotypes and outcomes and was by far the larger study with two large validation samples [54] . The authors proposed that increased P-glycoprotein expression with the CC genotype might result in increased cell growth, antiapoptotic effects on fibroblasts, promotion of cholesterolester mediated vascular damage, and increased propensity to ischemia-related injury as observed in animal models. Further, liver transplant recipients possessing the ABCB1 CC genotype had higher rates of post-transplant CKD.
It remains unclear why different ABCB1 C3435T polymorphisms are associated with increased allograft loss in the two reports [53, 54] . Neither study could account for potential gene-gene interactions relating to CNI pharmacokinetics and/or pharmacodynamics which could have influenced results. Furthermore, unaccounted environmental factors or recipient characteristics may explain the discordant results. As kidney donor ABCB1 CC genotypes more consistently demonstrated effects on renal allograft survival in the larger study [54] , future implications for transplant physicians may include selective use of CNI-free maintenance immunosuppression regimens to overcome the potential effects of donor-associated risk variants. We add that ABCB1 gene polymorphisms do not appear to significantly impact acute rejection, delayed graft function, or serum creatinine concentration after kidney transplantation [58] [59] [60] .
Conclusions
The current era of genomic medicine holds tremendous promise for improving outcomes in patients with ESKD who require kidney transplantation. It is particularly important that durable allograft survival from a first kidney transplant be achieved in pediatric, adolescent, and young adults with ESKD, particularly those with renal-limited disorders. These individuals have the best potential for long-term survival and are less likely to succumb with a functioning graft, relative to adult or elderly patients with systemic diseases such as diabetes mellitus. Much of the benefit from living related donation and six antigen HLAmatched deceased donor kidneys comes from associated lower rejection rates and need for lower doses of immunosuppression. We feel that the ongoing relative shortage of live kidney donors and use of more potent immunosuppression (with lesser emphasis on HLA matching) makes the effects of genetic polymorphisms that are present in donor transplant kidneys important to consider in the process of organ allocation. Laboratories can rapidly genotype deceased donors for the presence of risk variants in the APOL1, CAV1, ABCB1, and other genes as they are identified in the future. These variants may impact allograft survival and/or metabolism of immunosuppressants. Nearly 50 % of deceased donor kidneys harboring two APOL1 nephropathy risk variants will fail 3 years post-transplant.
We feel it is critically important that studies of kidney transplant outcomes include assessments of donor nephropathy risk variants and drug metabolism/pharmacogenomics. The best hope for long-term renal allograft survival will include transplanting kidneys with the fewest number of nephropathy risk variants, as well as optimizing potentially interactive environmental factors, such as reducing cold ischemia time and appropriately dosing immunosuppression to match the risk of rejection, interstitial fibrosis, and the transplanted kidney's ability to metabolize these medications.
